These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 14999610)

  • 1. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
    Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
    J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
    Hiransuthikul N; Hiransuthikul P; Kanasook Y
    Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    Fisac C; Virgili N; Ferrer E; Barbera MJ; Fumero E; Vilarasau C; Podzamczer D
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5186-92. PubMed ID: 14602748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in the lipid profile of dyslipidemic subjects.
    Kolovou GD; Anagnostopoulou KK; Damaskos DS; Bilianou HI; Mihas C; Milionis HJ; Kostakou PM; Cokkinos DV
    Eur J Intern Med; 2009 Mar; 20(2):145-51. PubMed ID: 19327602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.
    Bittar R; Giral P; Aslangul E; Assoumou L; Valantin MA; Kalmykova O; Fesel-Fouquier V; Costagliola D; Bonnefont-Rousselot D;
    Antivir Ther; 2012; 17(5):855-60. PubMed ID: 22318219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.